Phase 3 biotech developing therapies to treat ALS.
Industry: Health Care
Latest Trade: $2.97 -0.07 (-2.1%)
First Day Return: -4.9%
Return from IPO: -84.1%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 12/16/2021 |
Offer Price | $19.00 |
Price Range $18.00 - $20.00 | |
Offer Shares (mm) | 10.0 |
Deal Size ($mm) | $190 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 01/06/2022 |
Offer Price | $19.00 |
Price Range $18.00 - $20.00 | |
Offer Shares (mm) | 10.0 |
Deal Size ($mm) | $190 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Goldman Sachs |
Leerink Partners |
more |
Company Data | |
---|---|
Headquarters | Cambridge, MA, United States |
Founded | 2014 |
Employees at IPO | 110 |
Website www.amylyx.com |